Key Record Dates Identifier: NCT04209855
Brief Title: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

First Submitted : December 17, 2019
First Submitted that Met QC Criteria : December 20, 2019
First Posted : December 24, 2019

Last Update Submitted that Met QC Criteria : March 31, 2021
Last Update Posted : April 1, 2021